The Index
400 dossiers
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
agtech3 names· avg TR 1 | ||||||||
A | A cycle-trough, Europe-funded margin story trading at a deserved peer discount — own it for the 2026-27 ag recovery and the PTx self-help, but the entire thesis rests on EME holding up while North America bleeds tariff dollars and PTx Trimble proves it isn't a $2B impairment-in-waiting. | — | 1 | |||||
| A real ag-biologicals franchise (Rizobacter) trapped inside an over-levered Cayman holdco in going-concern doubt — creditors are credit-bidding the US crown jewels for cents, $222M of debt matures in FY2026 against $14M cash, and the equity at $0.42 is a near-worthless option on a restructuring, not an investment in the science. | — | 1 | ||||||
| A structurally-sound #2 ag-equipment franchise at trough earnings and a 0.84x EV/Sales — but the bull case rests on a 2027 cyclical recovery that tariffs, a self-inflicted precision-tech gap vs Deere, and Brazil credit stress can each defer. WATCHING — own the cycle turn, not the current print. | — | 1 | ||||||
ai9 names· avg TR 2 | ||||||||
| The market spent two years pricing Alphabet as the AI loser; FY2025 (+15% op income, Cloud margin to 24%, Gemini at 750M users, the antitrust gun mostly de-cocked) proves it owns the full stack — but at $4.5T and a fresh $90B+ capex habit, the easy re-rating is now behind it and the bar is "monetize the buildout." | — | |||||||
ai-bio14 names· avg TR 1 | ||||||||
| A de-risked, cash-rich option on one binary — ABCL635 Phase 2 hot-flash data in Q3 2026 — wrapped around a platform whose old royalty engine has gone to zero; the antibody-vs-pill differentiation is plausible but unproven, and at ~$1.5B the market is already paying for a win. | — | 1 | ||||||
bci4 names· avg TR 1 | ||||||||
| A genuine semiconductor moat wrapped around a sub-scale, still-unprofitable medtech — the Midjourney/Embedded licensing pivot is real and re-rates the story, but at ~10x forward sales with episodic licensing revenue and a founder selling, the price already imputes the platform it has not yet proven. | — | |||||||
biopharma9 names· avg TR 5 | ||||||||
A Altimmunecatalyst in 42d | A single-asset MASH/AUD/ALD bet on a glucagon/GLP-1 dual agonist that wins on liver biology and lean-mass-sparing but loses on raw weight loss — fully funded into 2028 with a binary AUD readout in Q3 2026 as the next free option; a derisked, heavily-shorted optionality vehicle, not a fundamentals compounder. | — | ||||||
critical-materials20 names· avg TR 2 | ||||||||
| A genuinely deleveraged, vertically-integrated aluminum pure-play whose 2025-26 earnings recovery is being borrowed from a tariff — ~60% of US aluminum volume rides a Section-232-inflated Midwest premium that is a policy decision away from evaporating; own the cycle, not the multiple. | — | 1 | ||||||
crypto30 names· avg TR 3 | ||||||||
A American Bitcoincatalyst in 44d | A Trump-branded, Hut-8-controlled bitcoin-accumulation SPV that sells equity to buy BTC and rents its mining from its parent — a ~3x-mNAV levered BTC proxy with no AI optionality, now down ~94% and asking holders for a 1-for-40 reverse split. | — | ||||||
datacenters24 names· avg TR 5 | ||||||||
| A global tower REIT mid-reset — DISH churn masks 4-5% organic + a CoreSite AI option the market half-ignores; quality compounding at a fair (not cheap) ~17x EV/EBITDA, with leverage and a 2026 "AFFO growth floor" the swing factors. BULLISH-leaning WATCH; conviction unlocks if 2027 reaccelerates as guided. | — | |||||||
electrification2 names· avg TR 1 | ||||||||
| A levered call option on US grid-storage demand and IRA/OBBBA domestic-content rules — record $5.6B backlog and two hyperscaler deals validate the funnel, but 7–13% gross margins, a 50%-H2-weighted year, and a stock above the average analyst target leave it priced for flawless execution it has repeatedly failed to deliver. | — | |||||||
energy32 names· avg TR 4 | ||||||||
| A best-in-class regulated growth utility whose 6–8% EPS CAGR is now under-written by real, contracted data-center load (2.2 GW signed) and ~10.6% rate-base growth — but the market already pays 20x for it, the FCF is structurally negative, and the entire thesis rides on Missouri and Illinois regulators staying constructive. | — | |||||||
genomics28 names· avg TR 4 | ||||||||
| A real consumables-led inflection (Q1 product rev +9%, 70% GM, FCF-positive) is fighting a settlement-inflated optical decline and a +73% YTD melt-up — the business is turning but the price already pays for the turn; WATCHING into the Atera-vs-installed-base cannibalization quarter. | — | 8 | ||||||
hardware28 names· avg TR 4 | ||||||||
| A China-domestic wafer-cleaning champion wearing a US ticker and a US growth-stock multiple — 99.6% China revenue, both operating subsidiaries on the BIS Entity List, margins compressing and FCF negative, yet priced at ~61x forward GAAP EPS. The business is real; the valuation is a different security from the fundamentals. | — | |||||||
optical-computing7 names· avg TR 1 | ||||||||
| A real, scarce, China-gated InP asset that AI-optics demand made strategic — but the stock already priced an ~80x melt-up to a ~$5.9B cap on an $88M-revenue, loss-making, single-country-manufacturing base; the asset is genuine, the multiple is a dare. | — | 1 | ||||||
robotics25 names· avg TR 4 | ||||||||
| A genuine FMCW technology lead and a watershed exclusive-OEM win, priced at ~28x forward sales against ~24 months of runway and a 2028 start-of-production — the technology is real, the chasm between here and revenue is the trade. | — | 1 | ||||||
space11 names· avg TR 3 | ||||||||
| A genuine post-COVID turnaround now firing on operating leverage (Q1 op margin 11.8%, book-to-bill 1.26, $734M record backlog) — but the stock already 3x'd to a ~64x trailing / ~27x forward P/E that prices the recovery as permanent, leaving thin margin of safety with a levered balance sheet and a live Lufthansa patent overhang. | — | |||||||
| The neutral arms-dealer of the AI build-out — AWS + Trainium + a stake in both OpenAI and Anthropic is the best-positioned compute franchise on Earth, but free cash flow has been incinerated to ~$1B and a ~$200B 2026 capex bet on 5-year-depreciated silicon is the whole thesis. | — | 1 |
C CoreWeavecatalyst in 45d | Extraordinary contracted growth ($60.7B RPO) on a leveraged, FCF-negative, accounting-aggressive balance sheet — a leveraged bet on the AI-capex cycle, fairly priced at ~$96 (mid-range of $67–192 analyst targets). WATCH; want a cheaper entry (~$70) or an FCF inflection before paying up. | — | 1 |
| The cheapest mega-cap AI franchise — DeepMind's full-stack (TPU → Gemini → 15 products) just proved monetization (Cloud +63%, $462B backlog, AI Overviews monetizing at parity), so the AGI optionality is a free call; the real bet is whether the Dec-2025 Search remedy survives appeal and capex discipline holds. | — | 1 |
| The best-funded, worst-priced AI franchise in megacap — a $200B+ ad engine bankrolling a $135B/yr superintelligence bet the market is refusing to underwrite; the stock pays you to wait while the ad-AI flywheel already prints, but the open-weight thesis is dead and the capex ROI clock is now running loud. | — | 1 |
| The cheapest mega-cap in the AI complex (~18–20x fwd P/E) compounding ad revenue +33% — but it has converted itself into a single-variable bet on whether $125–145B/yr of AI capex earns its return, and the market won't re-rate until the depreciation wave proves out. | — | 1 |
| The cleanest AI-infrastructure compounder on the board, now de-rated to ~20x forward on a real fear — Azure deceleration meeting a $190B/yr capex wall — that is more a timing question than a thesis-breaker; the moat (RPO $633B, M365 distribution, ~27% of OpenAI) is intact, the FCF is the variable to watch. | — | 1 |
| The FY26 10-K turns the bull narrative into audited fact and the bear narrative into a footnote you can now read — $67.4B revenue, $638B RPO, but only 12% converts inside a year, −$23.7B FCF, $129.5B debt, a 13% workforce cut, and a $19B post-quarter purchase commitment; good news kept beating and the stock kept falling (~$166, −52% from peak), which is the whole thesis in one line. | — | 8 |
| A genuinely great business priced as a perfect one — 85% growth and 60% adjusted margins are real, but ~55x EV/Sales already discounts flawless execution for years, so the asymmetry is to the downside even if the thesis is right. | — | 1 |
A Abscicatalyst in 42d | A re-rated single-asset AI-antibody story — ABS-101's half-life miss quietly killed the old lead, so the entire ~$1.15B cap now rides on one binary (ABS-201 alopecia interim PoC, H2 2026) against a 26%-of-float short and an 18-month runway. Own the readout, not the platform. | — | 0 |
| A debt-free clinical biotech trading below net cash after the FDA rejected its lead's trial design — the platform and a 4-year runway are free, but only if the EphA2/radioconjugate pivot proves the machine can make a second winner. | — | 1 |
| A real, regulator-embedded biosimulation moat trading like a broken SaaS roll-up — but the bet only works if the new CEO can re-accelerate software past the +7% Q1 stall before the M&A floor (SLP at 2.5x) is the only thing holding the stock. | — | 1 |
C Codexiscatalyst in 43d | A real platform with a lottery ticket attached — the legacy biocatalysis P&L is shrinking and the entire equity is a bet that enzymatic siRNA manufacturing (ECO Synthesis) becomes the standard before the cash runs out in 2027; the 4x off the $0.96 March low has front-run any GMP revenue. | — | 1 |
| A de-risked cash shell ($373M, no debt, ~$207M EV) wrapped around a still-shrinking lab-automation pivot — the balance sheet is the asset, the income statement is the warning; long the optionality only below cash, not the story. | — | 8 |
| A real carbon-recycling technology trapped inside a going-concern microcap — the science works, the business model to monetize it does not yet, and the equity is a binary on insiders (Khosla/Brookfield) funding a cohort-licensing pivot to cash-flow breakeven before dilution and Nasdaq erode it to zero. WATCHING with a bearish tilt. | — | 1 |
| The most-instrumented AI drug-discovery platform with the thinnest clinical proof per dollar burned — one real Phase-2 win (REC-4881/FAP) against a $2.2B accumulated deficit, smart-money exiting (NVIDIA, Mubadala out), and a $1.67B market cap that is now a binary bet on Najat Khan converting platform optionality into a registrational asset before the cash runway forces another raise. | — | 1 |
| A genuinely differentiated allosteric PI3Kα asset with a clean ~$642M balance sheet and runway to 2029 — but the entire equity is one Phase 3 readout (ReDiscover-2) into a class that just got a $3B Novartis validation and a first-line Roche incumbent; own the science, respect that the market is pricing a win. | — | 1 |
| A genuinely moated physics-based drug-design platform stapled to a cash-burning pipeline it can no longer afford to develop — the software is finally being valued like software (2.5x EV/sales), and the hosted transition is depressing the very revenue line the market punishes hardest. Buy the platform, not the headline P&L; the re-rate needs ACV reacceleration + one partnered pipeline win, not a clinical miracle. | — | 1 |
| A profitable biosimulation pure-play that the public market broke (Pro-ficiency wrote off ~$72M of a $100M deal, growth fell to single digits) — and is now exiting via a $18.50/sh all-cash Altaris take-private. The fundamental thesis is moot; the only live question is deal-closes-vs-breaks, and this closes (board-unanimous, 16% founder block locked, Q4-2026 close). Merger-arb, not a growth bet. | — | 1 |
| Not a tools company anymore — a sub-NAV cash shell mid-conversion into Treeline's oncology pipeline; the only edge is the deal-spread between ~$325M market cap and the ~$460M net cash being delivered, and that spread is a bet on Bilenker's KRAS/BCL6 readouts, not on CyTOF. | — | 0 |
| A real, fast-growing oncology-data + diagnostics franchise wrapped in an "AI" narrative it can't yet monetize — own the genomics flywheel, but the round-trip-flavored deals, 30-vote founder, and a CEO famous for cashing out cap the multiple until cash flow turns. | — | 1 |
| A fortress-margin vertical-SaaS monopoly trading at a growth-stock funeral price (~20x forward EPS, near 52-wk lows) because the market is pricing a Salesforce-Agentforce CRM war that threatens the contested ~40% (Commercial) while ignoring the defensible, faster-growing ~60% (R&D/Quality); BULLISH at $153 on a 1–3Y view, but the CRM-migration-to-2030 is a real, watchable execution overhang — not a phantom. | — | 1 |
H Hyperfinecatalyst in 43d | A real, FDA-cleared portable-MRI razor finally finding its blade — Q1 device units +67% and runway into 2028 de-risk the going-concern story, but at ~$22M revenue and a ~$140M cap it is still a sub-scale, founder-controlled call option on point-of-care neuro-imaging, not yet a business. | — | 1 |
| Cheapest large-cap medtech (fwd P/E ~13x, ~half of BSX/SYK) finally inflecting — PFA + Hugo + an Elliott-forced cost/portfolio reset put a credible re-rating in play, but the whole thesis rests on one unproven number: does organic growth hold above 5%? | — | 0 |
| A first-mover NGPS tools story whose commercial engine is going backwards (revenue −20% in FY25, −69% in Q1'26 to $258K) while it bets the company on Proteus by end-2026; ~$190M cash funds the bet, but a 69%-Rothberg-controlled sub-$1 microcap with collapsing instrument demand is a binary option, not an investment — WATCHING until Proteus ships and consumable pull-through proves real. | — | 1 |
| 1 |
| A levered dividend-compounder running a patent-cliff relay race — the legacy book (>40% of revenue under biosimilar/IRA attack) is being out-sprinted by Repatha/rare-disease/oncology launches, but the equity is priced for MariTide to win the obesity prize it most likely places, not wins, in. | — | 1 |
| A burned-then-reborn aging-biology platform whose entire ~$730M cap now rests on one Phase 1 asset (oral brain-penetrant NLRP3 inhibitor BGE-102) printing best-in-class hsCRP — fully funded to 2029, but the value-creating Phase 2 readouts are still 6-18 months out and a Lilly-backed competitor (ex-Ventyx) is the same molecule class with deeper pockets. | — | 1 |
| First-ever blood-brain-barrier biologic just got approved (AVLAYAH, Mar 2026) — Denali is now a de-risked platform with a small rare-disease revenue base, but the May LUMA Parkinson's failure gutted the biggest pipeline call option, so you're paying $3.3B for a ~$525M-peak orphan drug plus optionality the market just learned to distrust. | — | 1 |
E Equillium, Inc.catalyst in 44d | A two-asset preclinical option on EQ504 (gut-restricted AhR modulator for UC) wrapped in a >3yr cash runway and tier-1 (RA Capital / Decheng) sponsorship — but at ~$130–185M EV the market is paying real money for a drug no human has yet taken; the entire thesis lives or dies on the mid-2026 Phase 1 PoM readout ~early 2027. | — | 26 |
| A genetics-platform biotech whose lead asset just printed real proof-of-concept in a disease with zero approved drugs — and the stock fell 35% because Vertex's inaxaplin is two years ahead. The bet is whether oral once-daily APOL1 inhibition is a two-horse race or a winner-take-most one. | — | 8 |
| Lead asset is dead (navacaprant 0-for-3 in Phase 3 MDD, program killed Jun 15 2026); NMRA is now a ~$280M-cap shell with ~$130M cash, two early CNS shots (NMRA-511 AD-agitation Ph2, NMRA-898 schizophrenia Ph1) and runway into Q3 2027 — a busted-binary option, not an operating thesis. WATCHING, not investable, until an NMRA-511 Phase 2b signal or a credible cash-floor/M&A backstop appears. | — | 8 |
| Best-in-class *oral* GLP-1 efficacy in the wrong race — Structure has a genuine #2 asset and a fortress balance sheet, but Lilly's orforglipron is already approved (Foundayo, Apr 2026) and Structure's Phase 3 only *starts* Q3 2026, so the bet is whether a 2.9B-cap, ~2030-launch latecomer can carve share against the most powerful franchise in pharma. WATCHING, not yet a position. | — | 1 |
| The best obesity asset not yet owned by Big Pharma — but the market has already priced in a near-perfect Phase 3, leaving a binary 2027 readout where the upside is a takeout and the downside is a trap-door; SC maintenance data in Q3 2026 is the next real tell. | — | 1 |
| A copper compounder still priced as an iron-ore proxy — the re-rate is real but gated on iron ore not breaking before copper volumes arrive (2028+), and Jansen's serial cost blowouts are the tell that BHP's build muscle has atrophied. | — | 8 |
| The best-in-class Western uranium franchise with a free option on a nuclear-construction renaissance — but the market already owns it at ~35x forward EV/EBITDA and ~50x earnings, pricing the Westinghouse $80B build-out and a structural uranium deficit as near-certainties when the asset is operationally fragile (chronic mine shortfalls) and Westinghouse still loses money at the net line. Great company, demanding price; WATCHING for a multiple reset or an operational/contracting catalyst. | — | 8 |
| The only U.S.-owned enrichment platform with an NRC HALEU license and a $900M DOE expansion award — but it is still a sub-scale fuel broker living on a Russian supply contract that dies in 2028, priced at 50–60x earnings for a build-out that is contingent on money it does not yet have. | — | 1 |
| The single most tariff- and operationally-levered way to own a structurally walled-off US aluminum price — a high-beta, low-EV/EBITDA call levered to a record Midwest premium, gated by a Glencore-controlled cap table, a Jamalco material weakness, and a hedge book bleeding against its own thesis. | — | 1 |
| A leveraged, blast-furnace cyclical printing its worst losses since the acquisition spree — but the tariff-supported price floor is already bending the loss curve up, and the stock has nearly doubled off the low pricing much of that recovery in. Bullish on the operating turn, but the debt + dilution + cash-burn make this a high-beta option, not a compounder. | — | 1 |
| A world-class copper-and-gold orebody wrapped in a structurally leaky holding company — you buy FCX for the copper supercycle and the Grasberg restart, but ~half of every Indonesian dollar exits to the Indonesian state before it reaches your share, and Grasberg execution (not the copper price) is what actually decides the stock through 2027. | — | 1 |
| A levered, structurally-loss-making graphite-electrode pure-play whose old take-or-pay earnings are gone, now priced as a distressed call option on a 2026 electrode-price recovery that has to clear a 2029 debt wall — own the bonds' problem, not the equity, until pricing turns or the balance sheet is fixed. | — | 1 |
| A single-asset US copper developer (Santa Cruz) levered to a structural copper deficit and the "domestic critical-minerals" trade, wrapped in a Friedland promote and a still-unfunded $1.24B build — own the deposit and the EXIM optionality, but underwrite the dilution, not the PFS NPV. | — | 1 |
| The record 2026 print is mostly a Section-232 tariff-premium + metal-price-lag windfall on flat real volume — a high-quality fabricator priced for perfection at a 52-week high after a 2.5x run, with consensus already pointing down. | — | 1 |
| An irreplaceable U.S. beryllium monopoly wrapped in a low-margin pass-through metals business and now priced like a secular-growth compounder (~34x fwd vs 18-20x historical, above every Street target) — the asset is real, the multiple is the bet. | — | 1 |
| A subsidized option on Western rare-earth independence — the DoD's $110/kg NdPr floor turned a money-losing concentrate miner into a vertically-integrated magnet company with capped downside, but the equity already prices the 2028+ 10X build at ~134x forward earnings, so you're paying full freight for a thesis that depends on execution and elevated NdPr prices. | — | 1 |
| The tariff-fortified, lowest-cost EAF compounder is mid-upcycle with self-help volume still to land — but the +118% run already prices the recovery, so the edge is the multi-year normalized-earnings step-up, not the next print. | — | 1 |
| A de-risked, debt-light gold royalty toll-bridge that just doubled in size via Sandstorm yet trades at a ~7-9x P/E discount to Franco-Nevada and Wheaton — the discount is the thesis, not the warning. | — | 1 |
| The world's lowest-cost, longest-reserve, highest-margin copper pure-play — a generational asset wrapped in a Sell-rated price and 88.9% Grupo Mexico control; you want the orebody, not the multiple, and the market agrees. | — | 1 |
| Best-in-class low-cost EAF compounder riding a tariff-fattened spread into a stock that already prices the good news — the edge is the aluminum option and through-cycle discipline, not the current multiple. | — | 1 |
| The world's #1 vertically-integrated TiO2 producer is a high-quality asset trapped under an 11.1x-levered balance sheet in the worst pigment down-cycle in a decade — the equity is a leveraged call option on a 2027 cyclical recovery (plus a free rare-earth lottery ticket), not an investment, and the 2029 maturity wall is the clock. | — | 1 |
| A ~$1.1B market cap wrapped around a ~$40M-revenue, loss-making smelter — the only US vertically-integrated antimony producer, priced almost entirely on a back-end-loaded $125M federal-ramp promise from a serially-promotional CEO; own the antimony scarcity story, but the equity is a momentum/policy option, not a value asset. | — | 1 |
| A leveraged, no-reserves bet on the U.S. uranium-independence trade dressed as an operating miner — production is real but trivial, the share count is the business model, and at ~300x sales you are paying for the spot price and the policy narrative, not the P&L. | — | 1 |
| A pre-revenue mine-to-magnet roll-up that the U.S. government has chosen to underwrite — own the policy-protected build-out, not the ~240x-sales price; the bet is execution-by-2027, and the kill-switch is a single slipped milestone meeting a $5.5B valuation with $23M of revenue. | — | 0 |
| 1 |
| A leveraged Ethereum proxy that lives and dies on the mNAV premium — and the premium is already gone (trading ~0.75–0.89x NAV), turning the equity-issuance flywheel into a dilution headwind on a $9–10B ETH bet audited by a two-person Nevada CPA shop. | — | 1 |
| The toll-booth on the financialization of everything — ETFs, private markets, Aladdin, and now tokenized + crypto rails — trading at ~19x forward for low-double-digit organic-fee compounding; the bull case is "BlackRock IS the market," the bear case is that the market has finally noticed and is suing over it. | — | 8 |
| A payments compounder mid-turn — Cash App user growth is dead but Dorsey's 40%-headcount AI cut converts a flat top line into ~700bps of margin expansion and ~60% adj-EPS growth; the bet is on durable efficiency + on-balance-sheet lending working, against an AML/credit overhang. BULLISH/MEDIUM at ~16x forward. | — | 8 |
C Canaancatalyst in 44d | A real #3 ASIC maker that just clawed back to gross profit and product parity with Bitmain — but it is a sub-$1 going-concern call masquerading as a turnaround, where serial equity dilution and a hashprice depression decide the outcome long before the A16 does. | — | 1 |
| A bitcoin miner that has successfully optioned itself into an AI landlord — $11.4B of hyperscaler lease backlog backstopped by Google and Amazon is real, but the equity is priced for flawless execution of a buildout that hasn't started cashing rent, and the whole thesis is a bet on shovels-in-the-ground beating the sector's 25%-delivered track record. | — | 1 |
| A high-quality, regulation-first stablecoin franchise priced as a fintech but earning like a leveraged bond fund — the entire thesis now hangs on two August 2026 events (the Coinbase renegotiation and the rate path), and at ~$80 the market is paying for a re-rating that requires Circle to win both. | — | 1 |
| A best-in-class US bitcoin miner that has rebuilt itself into a 0%-convert-funded, share-shrinking BTC-beta vehicle now sprinting late into the AI/HPC pivot — the equity is a leveraged call on bitcoin and on executing a datacenter business that today earns exactly $0. | — | 1 |
| The regulated front-door to crypto with a real moat and a strengthening regulatory tailwind, wrapped around an earnings stream so volatile it just printed back-to-back GAAP losses — a ~70x-NTM-P/E call on crypto cycle timing dressed up as a fintech compounder; own the franchise, not this price. | — | 0 |
| A bitcoin miner that became an AI-datacenter landlord — the shareholders who killed CoreWeave's $9B buyout were right, and CoreWeave then handed them a $10.2B / 590 MW lease as consolation. The bet is now binary on one tenant. Bullish on execution, but it is a single-customer levered real-estate play priced like a software compounder (~20x sales) — own the buildings, fear the concentration. | — | 8 |
| A levered Solana proxy whose only value-creation engine — issuing stock above NAV to buy SOL — has stalled exactly as mNAV collapsed to ~1.0x; below par the flywheel runs in reverse and the $83M Q1 equity wipeout, three material weaknesses, and a SOL-collateralized margin book make this a forced-deleveraging short into the next SOL drawdown. | — | 1 |
| The best-run business in tokenized credit — a real, ~50%-EBITDA-margin lending-tech engine wearing a crypto multiple — but it is one HELOC product, one founder's super-vote, fresh material weaknesses and a million-record breach away from re-rating the wrong way; great company, priced like a story, own it cheaper. | — | 1 |
| A melting traditional active-manager (structural fee/flow decay, only WAM resolved) wearing a tokenization halo too small to matter yet — the BENJI option is real but ~0.15% of AUM; you are buying a 4% yield and a turnaround in active fixed income, not a crypto stock. | — | 8 |
| Two companies stapled together — a volatile crypto merchant bank wrapped around an emerging West-Texas AI-datacenter annuity (CoreWeave, >$1B/yr × 15yr); the stock has decoupled from bitcoin and now trades the Helios optionality, but CoreWeave single-tenant concentration plus a marked-to-market house book make conviction event-dependent, not durable. | — | 1 |
| A sub-1%-share, structurally subscale crypto exchange whose core trading revenue is already flat — kept alive by recurring related-party rescue financing from its own founders; the ~85% post-IPO drawdown is the market correctly re-rating a $3.3B IPO to a ~$0.5B going concern, and nothing in the numbers says the floor is in. | — | 1 |
| A 25 EH/s green Bitcoin miner that liquidated its entire treasury to fund a credible-but-unfunded pivot to AI compute — the stock now trades on a CAD $3.5B Gigafactory dream that $23M of cash cannot pay for. | — | 1 |
| A bitcoin miner that quietly turned into a hyperscaler landlord — ~$16.8B of base AA-/Google-credit lease backlog now dwarfs the BTC story, but the equity still trades and bleeds on bitcoin, and the Trump-adjacent ABTC sub is the governance hair. | — | 1 |
| A re-rating active manager hiding inside a melting active-mutual-fund book — the QQQ fee-switch and ETF/Asia flywheel are real and underpriced, but the same OppenheimerFunds intangibles it just wrote down $1.8B are the structural rot; quality-of-earnings and the MassMutual overhang cap the multiple. Net BULLISH-but-cheap-for-a-reason: a high-teens total-return name, not a compounder. | — | 8 |
I | A Bitcoin miner that won the AI-infrastructure lottery — NVIDIA both rents IREN's GPUs and bought its equity at $70, validating the liquid-cooling pivot Culper shorted; the bet is now execution and dilution, not survival. | — | 1 |
| MARA is a $5.7B-cap, 380M-share leveraged Bitcoin beta machine quietly trying to morph into an energy/AI-HPC landlord before its mining margins and its 2027 convert puts catch up with it — the AI pivot (Starwood JV, Exaion, the $1.5B Long Ridge gas plant) is the only thing that could break the "two-thirds-of-net-liability-is-just-a-BTC-ETF-you-pay-fees-on" trap, and it is 100% unproven (zero material AI revenue). At ~9x EV/sales with a -$1.0B Adjusted-EBITDA quarter just printed, you are paying a premium-to-spot-BTC for execution risk; bullish only if you are really just bullish BTC and want operating + dilution leverage on top. | — | 8 |
| A toll road on global consumption priced like a bond proxy — the moat is intact and value-added services are compounding at 2x the network, but the stock has de-rated to ~24x forward because the market is (rightly) pricing two live structural threats — stablecoin disintermediation and large-issuer network defection (Capital One/Discover) — that bulls keep waving away. WATCHING, lean BULLISH on weakness. | — | 8 |
| A Bitcoin treasury trading at ~0.33x mNAV with a name-brand promoter — the discount is the thesis and the trap; only a buyback-funded NAV-accretion flywheel or a takeunder closes it, and the Dec-2026 Kraken maturity is the clock. | — | 8 |
| A debt-free cash machine trading at 7-9x earnings with a 15%-of-float annual buyback — but the buyback is the whole thesis, because branded checkout (the high-margin core) is barely growing, transaction margin dollars are guided flat, the 2027 plan was withdrawn, the CEO was fired, and three securities class actions now allege the prior team hid the checkout slowdown. Deep value if Lores stabilizes checkout; value trap if the take-rate keeps bleeding. NEUTRAL-leaning-bullish on valuation, LOW conviction until checkout inflects. | — | 8 |
| A bitcoin miner whose P&L now swings on the BTC mark, not operations — repricing itself as a 1.7 GW AI/HPC power landlord on the back of one $311M AMD lease and a Starboard-pushed pivot; the ~$10.6B cap is paying for an optionality that is still 95% promise. | — | 1 |
| A real, cash-generative super-app now valued like a crypto-beta call option — the bull thesis (tokenization + a 27M-customer flywheel) is genuine, but ~37x forward earnings re-prices violently every time the crypto/options trading cycle exhales, and the prediction-markets engine that drove Q1 growth is one adverse court ruling from being switched off. | — | 1 |
| A profitable, fast-growing digital bank mispriced as a crypto name and now mispriced again by fear — but the entire bull/bear hinges on one binary question the market cannot yet resolve: are the +$2.0B of fair-value loan marks real, or is Muddy Waters right? | — | 1 |
| A levered, perpetual-dividend-funded bitcoin holding company whose entire accretion engine — issue stock above NAV, buy BTC — has inverted to a ~0.85x discount, so it is now SELLING bitcoin to pay an ~$0.9B/yr preferred coupon; bullish only as a bitcoin call, bearish as a structure, and the discount is the tell. | — | 0 |
| A coal-plant bitcoin miner that re-priced itself into a $14B "AI landlord" by renting power to a venture-stage neocloud — the equity is a levered call on Fluidstack actually paying, with Google's $3.2B backstop the only thing standing between the multiple and zero. | — | 0 |
| A negative-book-equity Solana levered fund wearing a consumer-products costume; with the stock at ~0.7x NAV, ~$185M of SOL-repayable convert/credit debt against a ~$165M treasury, and converts struck 4–5x above the share price, the equity is a deep-out-of-the-money call on SOL where bondholders own the first ~52% of the coins — BEARISH on the equity, structurally distinct from "owning SOL." | — | 8 |
V | A toll-road compounder mispriced as a disruption victim — 60%+ margins and 16% top-line growth are intact while the market discounts a debit antitrust loss and a stablecoin bypass that the numbers (cross-border +17%, $7B stablecoin run-rate is on-network, not against it) do not yet support; structurally BULLISH, but the DOJ debit case and the interchange settlement's final approval are real, dateable downside. | — | 8 |
| A real but sub-scale optical-transceiver share-gainer whose AI-data-center inflection is genuine — but the equity is priced as if it has already won a market that InnoLight, Coherent and Lumentum actually own, while it funds the build with relentless dilution and parks three-quarters of its receivables on one distributor (Digicomm) on stretched terms. The 2017 Amazon-loss crash is the template, not the exception. | — | 1 |
| The best-run pure-play in AI/cloud Ethernet — but it is priced for perfection (~46x fwd EPS) just as Nvidia's bundled Spectrum-X attacks its richest back-end AI sockets and two customers still drive 42% of revenue. Own the business, respect the multiple; the bear thread is real, not a strawman. | — | 8 |
| A genuine pick-and-shovel monopoly on PCIe-Gen6 datacenter connectivity, growing 90%+ with 76% gross margins — but priced at ~26x forward sales with one customer (AWS) at ~70% of revenue; the moat is real, the price is the bet. | — | 1 |
| A real business finally inflected to GAAP profit on the AI-power boom — but the stock is priced as if the 2.8 GW Oracle deal is the floor, not the ceiling; the asymmetry now runs short. | — | 0 |
| Real AI-optical winner caught at a euphoric, deeply cyclical top — the business inflected for real (FY26 rev +32% to $6.3B, adj op-margin ~19% vs a 4.8% FY24 trough), but at ~70x forward / ~10x EV/sales the stock is pricing permanence onto a name whose own 5-year record is 14.5%→4.8% margin and a -49.5% drawdown. BULLISH business, BEARISH-into-strength the entry. WATCH for the cycle to breathe. | — | 8 |
| Real AI-optical winner with a genuine fusion/fiber moat and an early-beat Springboard, but the stock has been re-rated to ~46x forward / ~11x EV-sales on a hyperscaler-concentrated capex bet — the business is BULLISH, the price is priced-for-perfection; WATCHING for a multiple reset, not chasing $212. | — | 8 |
| A real, durable AI-infrastructure winner trading like one — the growth is unimpeachable but the margin (mid-single-digit AI op-margin) and the AP-funded working-capital engine mean the bull case is now priced; WATCHING for a memory-cost or AP-normalization air-pocket to get paid. | — | 8 |
| The AI-era landlord with the cleanest balance sheet it has had in a decade — but the moat is durable, the price already pays for it; an own-the-toll-road BULLISH at a watch-on-pullback price, not a fat-pitch entry. | — | 0 |
| The interconnection monopoly the AI bears mis-modeled — Hindenburg's accounting case is legally dead, recurring revenue is re-accelerating into the AI inference build-out, and the 24.6x forward AFFO is a fair price for the one data-center asset with a real network-effect moat; the live risk is that AI's center of gravity sits in wholesale, where EQIX is structurally light. | — | 0 |
| A debt-free, founder-controlled electrical/mechanical contractor compounding EPS ~50%/yr on the data-center build-out — a genuinely great business, but the tape has run to ~38x trailing on TTM EPS ~$19 and ~13.8B mkt cap, pricing in continued hyperscaler capex and flawless M&A integration with a residential anchor already dragging; WATCHING, not chasing, into the next print. | — | 8 |
| A quietly excellent RF-and-photonics compounder that the market has finally noticed — fab-lite 56% gross margins, three secular legs (defense, AI data-center optics, telecom), a net-cash balance sheet after killing its 2026 converts, but now priced at ~54× forward with an AI-optical multiple it must keep compounding into; great business, demanding entry. | — | 8 |
| Best-positioned #2 in the custom-AI-silicon duopoly with an NVIDIA-blessed optical moat — but at ~$310 / ~109x trailing non-GAAP EPS the stock has priced in flawless execution AND already round-tripped a 2025 Trainium-loss scare; own the business, fade the entry, wait for a hyperscaler-wobble re-rate. | — | 0 |
| A 109-year-old radiator maker that 80/20'd itself into a data-center liquid-cooling growth story and got re-rated 14.7x in five years — the asset is real and a single hyperscaler has pre-committed >$4B of cooling for CY27–29, but at ~38x forward / ~133x trailing the price already pays for flawless execution while Q4 just showed the margin and supply-chain cracks that flawless execution doesn't have. Own the post-RMT pure-play on a data-center capex scare or a second margin miss — not here. | — | 8 |
| One week on, the thesis is unchanged but the price has cooled (~$291 → ~$260) into the closest-peer gap — and the bear case got SHARPER, not softer; two new sell-side teardowns now quantify a $10-15B FY2026 funding gap (~$29B external by 2028) while CoreWeave's backlog ballooned to ~$99B at a fraction of NBIS's revenue multiple. Still WATCHING; the funding-execution gate is the whole call. | — | 8 |
| The purest listed pick-and-shovel on the grid + data-center capex supercycle, with a real labor/scale moat and a record $48.5B backlog — but at ~52x forward EPS / ~31x forward EBITDA the market already pays for flawless execution, so the edge is in buying the volatility, not the multiple. | — | 8 |
| A best-in-class tower compounder having its worst year in a decade — 2026 AFFO/share is guided DOWN on DISH+Oi+Sprint churn and refinancing, and the M&A premium has fully bled out of the stock; structurally bullish for 3Y, but no rush at 15.5x AFFO with the churn cliff still in front of it. | — | 1 |
| A great business priced as a perpetual-motion machine — STRL is the highest-margin pure-play picks-and-shovels name on the AI/data-center buildout (E-Infra 60%+ of revenue, 23%+ segment margins, 2.1x book-to-burn, EPS up ~5x in three years), but at ~80x trailing / ~50x forward and ~4x intrinsic on a deeply cyclical, single-theme, customer-concentrated contractor, the quality is real and the price already capitalizes a flawless decade. WATCHING, not chasing — the dip is the trade, not the breakout. | — | 8 |
| A real AI-server demand engine (sold-out Blackwell, $39B order book, best-in-class DLC liquid cooling) wrapped in the worst governance dossier in large-cap tech — a co-founder/director under federal export-control indictment, still-unremediated SOX material weaknesses, ~10% gross margins half of Dell's, and a freshly-printed $7B dilutive raise. The business works; the trust does not. WATCHING, not ownable, until the forensic overhang resolves. | — | 1 |
| A small-float nuclear-and-gas IPP that turned one AWS contract into a re-rating; the moat is the irreplaceable 2.5 GW Susquehanna campus, the risk is that the price already capitalizes a decade of PJM scarcity and premium PPAs that policy can cap. | — | 1 |
| A $2.8B equity wafer balanced on an $11B junk-rated debt tower — the whole thesis is whether Kinetic fiber penetration ramps EBITDA fast enough to delever before the 2028–2031 maturities, and the market has already paid up for that bet. | — | 1 |
| The default arms dealer of the AI buildout — a real moat compounding a $15B backlog into 30% organic growth, but priced at 82x for perfection while insiders sell 65:0 and EMEA orders are already cracking. | — | 8 |
| A merchant-power balance sheet wearing a regulated-utility's contracted growth — long-dated nuclear PPAs to AWS/Meta de-risk the AI-demand story, but the GAAP P&L is hostage to hedge mark-to-market and the equity carries ~3.4x the net debt of Constellation. Cheapest large-cap way to own the data-center power trade if (and only if) ERCOT/PJM load growth shows up; bull at ~10x forward EBITDA, but leverage + commodity beta make it the high-volatility expression, not the safe one. | — | 8 |
| A real, cash-generating neocloud retrofitter trading at ~18x trailing sales on a single $865M Nscale contract and a still-71%-Bit-Digital-controlled cap table — the build is genuine, but the multiple already prices the NC-1 inflection that hasn't happened yet. | — | 1 |
| A genuine ceramic-separator moat wrapped around a capital-light VW/PowerCo license — but the equity is a $4.4B option on a $130M royalty cheque that has NOT yet been triggered, burning ~$60M/quarter of cash against a binary milestone it does not control. | — | 1 |
| A real, first-mover aviation/drone battery franchise inflecting to its first profitable year — but priced at ~17x guided 2026 sales with a China related-party supplier (Berzelius, ~36% of COGS, tied to the founder) now the subject of an active short report; the franchise is bullish, the stock is a show-me on revenue quality. | — | 1 |
| A compounding life-safety roll-up with a genuine recurring-revenue flywheel and a top-tier capital-allocation board — but at ~20x EBITDA / ~25x earnings, ~53% of the balance sheet in goodwill+intangibles, and a thesis fully dependent on Becker's M&A machine never missing, the quality is real and mostly priced. WATCHING; buy the air-pocket, don't chase the print. | — | 8 |
| A profitable-at-the-EBITDA-line, 100%-domestic-content solar-tracker #2 trading at half Nextracker's multiple — but the equity is a thin slice trapped beneath $400M of compounding 6.25%→cash preferred, a collapsed Brazil segment, and a 2026 OBBB safe-harbor cliff that turns its record order book into a coin-flip on timing. | — | 1 |
A ASP Isotopescatalyst in 44d | A pre-revenue isotope-enrichment story trading on three real Western-monopoly catalysts (Yb-176, Si-28, HALEU) — but the FY25 "revenue" was construction it has since deconsolidated, the GAAP loss is a $124M convertible-note mark, and the tape is a 22%-short battleground stuck in active securities-fraud litigation. The science could be a generational supply-chain unlock; the accounting and promotion are exactly what shorts say they are. WATCHING, not yet ownable. | — | 1 |
| The best-run pure-play gas LDC compounding rate base ~14%/yr behind a fully-tracked recovery machine — but the NTSB just named its own leak-management program the probable cause of two fatal Mississippi explosions, and the stock already prices the growth at ~20x with a thin 2.25% yield. Quality is real; the entry is not cheap and the safety overhang is a live, uncapped tail. | — | 8 |
| The only North American sole-source maker of naval reactor cores plus the first US microreactor — a genuine monopoly franchise compounding off a record $8.65B backlog, but the tape has already paid ~43x forward earnings for that quality, so the entire bull case from here is multiple-defense, not business risk. | — | 0 |
| A best-in-class regulated grid-build story (8%+ rate-base CAGR, $25.8B 5-yr capex, ~9 GW data-center pipeline that LOWERS customer rates) trading at a defensible-but-not-cheap ~19x forward P/E — the bull case is sound, but the stock is already a market-rate hold (consensus PT ~$80 vs ~$74), so the edge is timing the data-center contract-signing catalysts, not the multiple. | — | 8 |
| A flawless, fully-regulated NYC rate-base compounder priced like one — ~17.5x forward earnings and a 9.4% allowed ROE buy you a bond-proxy 6–7% EPS/dividend grower, not alpha; the asymmetric risk is political (NY rate-hike backlash + gas-ban terminal value), not operational. WATCHING, would own on a yield > ~4% reset. | — | 8 |
| A de-risked regulated growth utility hiding inside a decade-long value-trap reputation — the Loudoun County data-center boom is the largest demand tailwind in US utilities, but the equity only re-rates once CVOW finishes clean and the dividend finally grows; until then you are paid ~3.9% to wait on a BBB+ balance sheet stretched by a $65B capex plan. | — | 8 |
| A bond proxy that quietly turned into an AI-load growth stock — the cheapest large-cap regulated utility (18.9x) is being handed the largest capex plan in the industry ($103B) and a 4.5GW data-center backlog, but the entire re-rate hinges on a hostile North Carolina commission letting it earn on that base. | — | 0 |
| The purest listed pick-and-shovel on the AI datacenter electrification build-out — net-cash, 28% ROE, record $15.6B backlog — but the easy re-rate is done; at ~26x forward EPS you are now paying full price for a cyclical contractor whose margin and backlog both sit at all-time highs. | — | 0 |
| A pre-commercial silicon-anode battery story trading at ~$1.6B on $32M of lumpy Korean-defense revenue — the entire thesis is one flagship smartphone qualification that keeps slipping; brilliant architecture and an A-list mobile CEO, but until a real OEM ships, this is a binary, dilution-exposed option, not a business. | — | 1 |
| A microinverter monopoly-economics business being repriced as an "AI-power" growth story while its core market is in a policy-driven cliff — the hardware/cash flow is real, the data-center narrative is a call option the multiple already pays for. Net NEUTRAL/WATCHING: own the violent rerating only on proof the 45X cash engine survives FEOC and the non-residential mix actually scales. | — | 8 |
| A real zinc-battery business is finally being born inside a financial engine that mints non-cash "profits" while burning ~$120M/quarter in cash and diluting holders 49% a year — own the inflection only if you believe COGS crosses below revenue before the Cerberus-and-convert capital structure swallows the equity. | — | 1 |
| A de-risked pure-wires utility trading at a ~15x discount because Connecticut's regulator and FERC keep clipping its allowed returns — re-rates only if the CT "constructive shift" is real and the FERC ROE appeal claws back basis points; the AI-power bid does not apply here. | — | 8 |
| A post-scandal regulated T&D pure-play repricing from "governance-risk discount" to "data-center transmission growth" — owns the right wires (24,000 mi, PJM, +45% peak load) and a credible outsider CEO, but the thesis is a 6–8% EPS-CAGR rate-base compounder, not a multibagger; Householder-related securities litigation (loss "probable", unestimable) and Baa3 balance-sheet tightness are the live tail risks. | — | 8 |
| The best-run solar manufacturer on earth, but ~$1.6B of FY25's $1.5B net income is a US tax credit — you are not buying a module company, you are buying a leveraged, policy-dated bet that the 45X subsidy and the domestic-content wall hold through 2032. | — | 1 |
| A 28-year-unprofitable, perpetually-dilutive fuel-cell manufacturer re-rated 135% YTD on an AI-data-center pipeline that is still non-binding LOIs — the story is real, the order book is not, and the funding model is the share count. | — | 1 |
| The purest non-utility way to own the AI-electricity buildout — a #2 infrastructure E&C contractor whose record $20.3B backlog and 34% Q1 growth are real, but the stock already prices ~40x forward EPS, so the bet is on the cycle's *duration*, not its existence. | — | 8 |
| A real operating turnaround (FY25 first positive operating income, +$76M operating cash) trapped inside a busted-SPAC capital structure, a going-concern flag, and a -48% Q1 air-pocket — cheap at ~0.3x sales but the convertible loan and demand lumpiness make it a high-variance WATCHING, not a buy until the next two quarters prove FY25 wasn't the peak. | — | 8 |
| A regulated Florida-utility crown jewel (FPL) bolted to the world's largest renewables developer (NEER), trading at a 22x premium that prices the AI-power supercycle as a sure thing while the OBBBA tax-credit cliff and a $95B debt stack sit unpriced — own the moat, but the multiple already pays for the catalyst. | — | 0 |
| The dominant solar-tracker franchise (>50% US, ~30% global, 11 straight years #1) with a clean, net-cash balance sheet and a beat-and-raise FY26 — but the FY27 guide already flags margin compression, and the whole bull case rests on developers safe-harboring around the OBBBA placed-in-service cliff (Dec 31 2027) plus a 45X manufacturing subsidy (~$380M, ~10% of revenue) that phases out 2030–2032. Quality is not in question; the multiple (~26x forward P/E, ~3x peer ARRY) and the policy clock are. | — | 1 |
| A boring Indiana gas/electric utility that quietly became an AI-power landlord — a ~$28B 2026-30 capital plan, ~9GW of hyperscaler demand funnelled through a Blackstone-capitalised ring-fenced GenCo earning an unlevered IRR the 10-K says should BEAT its regulated return, and a 9-10% EPS CAGR the market is paying a deserved ~22-23x for. Own the contracted re-rate; the kill-switch is Amazon exercising its Mar-2029 option to halve the ADS contract. | — | 1 |
| A boring enclosures-and-connectors company that bought and sold its way into the AI data-center build — now growing 50%+ with infrastructure orders up 100% organically; the re-rating to ~28x is largely earned, but the multiple now prices in the build continuing, and the legacy two-thirds of the business is still cyclical late-cycle industrials. | — | 1 |
| A real cost-down turnaround grafted onto a structurally unfinanceable business — burn is halving and the going-concern flag is gone, but the company still funds itself by printing ~450M shares a year; the operations are improving faster than the cap table is being destroyed, but not fast enough to own the equity until EBITDAS-positive (4Q26 promise) is on the tape. | — | 8 |
| A 90%-regulated New Jersey wires utility wearing a merchant-nuclear data-center costume — you are paid ~17x for a 6–8% regulated compounder, and the AI-power optionality is real but unpriced *and* unproven; own it as a rate-base bond with a free nuclear call option, not as the next Constellation. | — | 0 |
| A re-accelerating solar-EBOS niche-monopolist (FY26 guided +30%, record $758M backlog, IP win pending) trading at ~27x fwd P/E on a near-empty balance sheet ($1.9M cash, revolver 91% drawn) — the growth is real but the equity is priced for it and the funding runway is the actual risk, not the (now-settled) shrinkback overhang. | — | 1 |
| A real turnaround that has already been paid for — six straight quarters of margin repair and the return to positive operating cash flow are genuine, but at ~$60 the stock prices in a clean, AMPTC-independent recovery the filings explicitly say does not yet exist (ex-45X credits, SolarEdge is still gross-loss-making), so the asymmetry from here is poor. | — | 1 |
| A regulated-utility levered call on the Georgia data-center build-out — the cleanest large-cap way to own AI power demand, but priced as if the affordability politics and equity dilution won't bite; own the growth, respect the ~24x multiple. | — | 0 |
| A consolidating monopolist on a leveraged treadmill — RUN's GAAP "profit" is an HLBV mirage, but the OBBBA's asymmetric kill of 25D (not 48E) hands the TPO leader the residential market it can't yet profitably finance; the bet is whether ~$15B of non-recourse debt rolls before rates or a securitization-market hiccup forces a dilutive reset. | — | 1 |
| A de-risked regulated-utility play on the data-center power buildout — the PSCW's April-2026 verbal approval of the VLC/Bespoke tariffs converts a $37.5B capex plan into a rate-base annuity, but at ~20x forward EPS the re-rating is mostly priced and the upside now lives in 2028 acceleration, not the multiple. | — | 8 |
| A negative-EV ($-60M) clinical-stage AAV play where the market prices the entire pipeline below cash — fully funded into 2H 2028 with two binary Phase 3 wet-AMD readouts (4FRONT-1 1H'27, 4FRONT-2 2H'27) standing between it and either a re-rate or a wipeout; best-in-class intravitreal tolerability is the edge, durability-vs-Eylea-HD/faricimab is the kill switch. | — | 1 |
| A high-quality, recurring-revenue lab-tools compounder whose cyclical trough is over and whose margins are inflecting — but at ~20x forward EPS the recovery is already largely priced; the asymmetry is a beat-and-raise grind, not a re-rating. | — | 8 |
| The first RNAi company to scale to profitability — Amvuttra's ATTR-CM launch turned a 20-year science project into a >$5B-revenue franchise inflecting at +71% guided; the bet is whether durable TTR leadership + a 40-program pipeline justify ~70x forward earnings before nucresiran fixes the Sanofi royalty drag. | — | 1 |
| A platform-validated RNAi engine the Street prices as a partnering machine, not a commercial one — the entire bull case is whether plozasiran's sHTG sNDA (YE2026) turns a $15.2B milestone option-stack into owned product P&L before the 15% PIK debt and serial dilution grind down the equity. | — | 1 |
| A €17bn cash fortress wrapped around a melting COVID annuity and one make-or-break fast-follower oncology bet (pumitamig) — the founders just announced they're walking out the door, and the market still pays a premium for a pipeline that is, so far, the second-best PD-(L)1×VEGF in the world. | — | 1 |
| "Real, accelerating transplant-dx franchise that just turned GAAP-profitable and is reshaping itself (sell low-margin kits, buy oncology MRD) — but ~46% of its core segment still rides on a single Medicare LCD that CMS has confirmed it will re-issue; a quality compounder priced for the good case with a binary policy fuse attached. WATCHING, leaning constructive, gated on the new LCD." | — | 8 |
| An $44M-EV option on allogeneic CAR-T — the market prices the pipeline at zero while the durability data quietly de-risked; the bet is binary on ANTLER-3 financing, not on the science. | — | 8 |
| The only commercial CRISPR company is a Vertex-controlled 40% royalty stub bolted to a self-funded in-vivo pipeline — own it for CTX310/zugo-cel optionality, not for Casgevy, whose cell-collection bottleneck caps the near-term cash story. | — | 1 |
| A foundational-CRISPR IP estate wrapped around a single, late-arriving preclinical asset (EDIT-401) — a binary 2026-2027 LDLR bet that is years behind Lilly/Verve, now fully funded into 2027+ by a May 2026 raise that diluted holders ~25%; the moat is real, the pipeline is not yet. | — | 1 |
| A debt-free diagnostics lab trading at ~cash with a real, free oncology call option (FID-007) — but you are paid to wait through a 2026 revenue air-pocket and an unquantified HRSA/DOJ False-Claims tail larger than the market cap. | — | 8 |
| A profitable liquid-biopsy oncology franchise quietly cross-subsidising a binary, USPSTF-gated bet on blood-based cancer screening — the re-rating from $52 to $130 already paid for the Shield optionality, so from here you are paying ~11x sales to be long a single 2026 guideline decision. | — | 8 |
| A real operational turnaround is underway (rev re-accelerating, margins expanding, share count shrinking), but the stock has already sprinted past consensus into a Roche-Axelios competitive collision and a 40%-NIH-cut research recession — the easy money in the recovery is made. | — | 1 |
| A de-risked HAE asset (lonvo-z, 87% attack cut, BLA filing) wrapped in a financing-and-competition problem — the cure is real, the question is whether anyone buys a one-shot in a market with 11 approved drugs, and whether a $1.9B-cap, 38%-shorted clinical-stage burner reaches launch without another dilutive raise. | — | 1 |
| A real RNA-medicine platform finally turning into a P&L — but the stock is a pelacarsen option with seven launches as the floor. Own the platform, size for the binary. | — | 8 |
| A genuinely profitable, self-funded in-vivo gene-therapy platform whose entire growth narrative now rests on ex-US VYJUVEK launches (US is flat) plus an unhedged binary KB707/NSCLC option — priced at ~23x sales as if both already work. | — | 0 |
M MeiraGTxcatalyst in 44d | A de-risked gene-therapy platform hiding inside a $0.85B shell — bota-vec reacquisition + Lilly/Hologen non-dilutive funding gives MeiraGTx three near-term shots (xerostomia BTD, XLRP filing, riboswitch-GLP1 optionality) the market is pricing as one coin-flip; the bet is on execution-to-launch, not science. | — | 1 |
| A real mRNA platform priced like an oncology winner before the oncology has won — the +94% YTD melt-up has run past a still-burning, policy-exposed vaccine business with a $1.3B IP tail. | — | 1 |
| A category-defining MRD franchise compounding ~35-40% with newly-positive FCF, but priced at ~13x sales for a still-GAAP-unprofitable company whose reported losses are masked only by $350M+/yr of stock dilution and a litigation rap-sheet (a $292.5M Guardant verdict on appeal) that the multiple ignores. | — | 1 |
| A long-read pure-play with improving razor-and-blade economics and a real cost roadmap, structurally outrun by Oxford Nanopore and pinned under $641M of out-of-the-money 2029/2030 converts it cannot grow into — a cash-discipline turnaround, not yet an investable one. | — | 1 |
| A David Liu-pedigreed prime-editing pioneer cornered into a defensive crouch — 25% RIF, founder-CEO out, lead CGD asset demoted to a partnering candidate, going-concern doubt at ~14 months of cash, and an existential Beam IP arbitration over one of its two surviving lead programs. At a ~$537M cap it is a deeply discounted binary call option on 2027 first-in-human liver data; bullish only for risk-seeking capital that can survive a dilution-or-bust 2026. | — | 1 |
| A cash-generative #2/#3 molecular-diagnostics toolmaker trading at a tools-sector discount (~15x fwd P/E, 4x EV/sales) because its single most profitable franchise — QuantiFERON, ~24% of sales — just lost its US-immigration-testing growth engine and cratered FY26 to +1-2% CER; the stock is a recovery/strategic-options call (it sits ~25% below the 2020 Thermo Fisher takeout it rejected, with two activists on the register), not a growth-compounder bet. | — | 8 |
| A one-asset, binary bet on a genuinely best-in-class disease-modifying Dravet drug whose pivotal read-out (mid-2027) lands inside a fully-funded runway — own it for the read-out, but size it like the 50/50 single-trial event it is. | — | 1 |
| A clean-safety, single-asset Rett gene-therapy bet that just de-risked into a one-binary stock — H1'27 6-month pivotal interim + FDA BLA feedback is the entire thesis; an AveXis-grade operator and a competitor's patient death make the asymmetry real, but at a ~$1.8B cap on zero revenue the bear case is "single-trial, single-indication, dilution-funded." | — | 8 |
| The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to. | — | 0 |
| A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding. | — | 8 |
| A rare profitable, debt-free genomic-dx compounder (FY25 16% rev growth, $126M FCF) — but the stock has doubled into a 6.5x-sales / ~30x-FCF valuation just as Natera's FDA-approved Signatera CDx occupies the exact MIBC beachhead TrueMRD is launching into. Quality business, priced for flawless MRD execution it has not yet proven. WATCHING; would buy a reimbursement/launch-driven pullback under ~$40. | — | 8 |
| Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket. | — | 1 |
| The number-two AI compute franchise is finally real (DC $16.6B FY25, MI450/OpenAI 6GW signed) — but at ~58x forward EPS with 320M warrant shares of dilution overhang and an analyst PT below spot, the stock has already priced the win. WATCHING, not chasing. | — | 1 |
| A real, recovering analog franchise (TMR current-sensing + auto/data-center) trading like a hyperscaler — the business is fixed, the stock is not cheap, and a ~32% Sanken overhang still wants out. | — | 8 |
| A genuine edge-AI vision SoC franchise finally inflecting to growth and operating leverage — but it is still GAAP-unprofitable, ~70% revenue routes through one distributor, and the stock prices both a re-acceleration AND an unresolved M&A bid. Quality asset, demanding price, binary catalyst. | — | 1 |
| A 90-year connector compounder that the market has re-rated into an AI-infrastructure growth stock — the business is exceptional and the AI cycle is real, but at ~34x forward EPS and 50% above its own decade-average multiple, the price already pays Amphenol to keep printing 30%+ organic growth, leaving no cushion if hyperscaler capex normalizes. | — | 1 |
| A best-in-class analog compounder mid-way through a violent cyclical recovery — the business is pristine, the cycle is real, but at ~35x forward / ~65x trailing the tape has already paid for the upturn; the edge is in the next destock, not at today's price. | — | 8 |
A Applied Materialscatalyst in 45d | The cheapest of the four equipment leaders riding a re-accelerating AI/GAA WFE upcycle — but the entry is a 4x-off-the-low all-time high, and the bet is whether the >30% 2026 equipment-growth guide is the new floor or a cycle peak being paid for in advance. | — | 1 |
| A genuine architectural toll-road compounding at 20%+ with a real second engine (Armv9/CSS rate expansion + first-party AGI CPU) — but priced for a decade of flawless execution (~180x GAAP / ~200x non-GAAP P/E, Street mean ~38% below spot) just as it picks a channel-conflict fight with its own licensees and loses the Qualcomm weapon that defined its moat. BULLISH business, BEARISH price — WATCHING for a multiple reset. | — | 0 |
| The one company AI cannot route around — a literal EUV monopoly compounding at mid-teens with a fortress balance sheet, priced at ~55x for perfection while the only real bear (a China DUV ban naming ASML in statute) caps the downside at ~5% of revenue. Own the moat; respect the multiple. | — | 1 |
| A toll-booth on the AI-silicon boom with 86% gross margins and an $8B backlog — but priced for perfection at ~42x forward earnings while the agentic-AI upsell that justifies the multiple is not yet in the model and a fresh DOJ guilty plea caps the China optionality. Quality is not the question; the entry price is. | — | 8 |
| The pure-play AOI/metrology pick on the HBM-and-chiplet inspection supercycle — >40% HBM-inspection share and 50% of revenue now AI-driven — but a ~50x forward multiple already prices the boom while 49% China revenue sits under a tightening export-control gun. | — | 8 |
| A real, broad-based analog/discrete cyclical recovery (5 straight quarters of double-digit growth) onto which the market has bolted a ~2x re-rate to ~38x fwd P/E — earnings are inflecting up, but the stock now prices the 40% gross-margin dream as if it already arrived; the asymmetry is bearish-into-strength, not bullish. | — | 8 |
| A real, well-run subsystem turnaround riding a genuine WFE upcycle — but at $98 (7x off the lows, EV/EBITDA ~23x, ~32x forward EPS) the stock has front-run the margin story it hasn't yet delivered; the sell-side target ($81.71) now sits BELOW the price and insiders are selling. WATCHING, not chasing — the edge is on a pullback to ~$60s or a Q2 margin miss, not here. | — | 8 |
| A barely-profitable IDM whose equity 10x'd on a recapitalization-and-validation narrative (US gov, Nvidia, SoftBank, hyperscaler 18A interest) while Foundry still bled $10.3B in FY25 — the story is priced as if the turnaround already happened. WATCHING, with a bearish lean on valuation. | — | 1 |
| Best-in-class etch monopoly riding a once-a-decade memory/AI WFE upcycle into record margins — but at ~69x guided FY26 GAAP EPS the tape, not the business, is the risk; the moat is real, the multiple is borrowed from the future. | — | 1 |
| A real AI-optical DSP ramp (Keystone/Rushmore) bolted onto a flat legacy-broadband body and an unreserved $160M+ arbitration — the stock at $89 already prices the pure-play outcome the income statement hasn't earned; the 80% post-Q1 spike has run past sell-side fair value ($68). | — | 1 |
| A genuinely elite fabless analog compounder (43% 5yr ROIC) that has become a high-beta levered call on Nvidia's power-delivery socket — priced at ~112x trailing / ~49x NTM EV-EBITDA (peer median ~21x) while carrying an unremediated material weakness, an adverse ICFR opinion, and a live securities class action. Own the franchise, not this multiple; the gap between the Vera Rubin "70% share" dream and the Blackwell "allocation-at-risk" reality is the whole trade. | — | 0 |
| A #2 process-control specialist compounding revenue at ~1.7x the market on a structural metrology-intensity tailwind and an AI-memory cycle — but priced at ~35-48x forward earnings with one customer at 23% and a third of sales in export-control-exposed China; own the business, respect the price. | — | 1 |
| Best franchise in AI infrastructure at an undemanding 21x forward — but revenue quality is migrating to the balance sheet (54% customer concentration + a circular-financing loop), so this is quality-at-fair-price, not mispriced growth. BULLISH / MEDIUM / 1Y. | BullishMed | 12 |
| A 3-engine specialty-hardware roll-up wearing an "AI factory" costume — the AI-systems story (Advanced Computing) is the lowest-margin, most lumpy, most hyperscaler-concentrated leg, and the actual FY26 EPS beat is being driven by a cyclical memory (DRAM/Flash) price spike that the bulls are extrapolating as if it were the AI thesis; own the re-rating only if you trust the Shaikh-led non-hyperscaler pivot to convert before the memory cycle rolls. | — | 8 |
| A licensing-fortified cash machine being paid ~20x forward NOT to lose a $7B Apple leg it is already losing — the rerate only comes if Snapdragon-X PCs + custom data-center silicon replace Apple faster than handsets fade, and the tape (rev −3% YoY, Q3 guide −7%) says it isn't there yet. | — | 0 |
| A genuine deleveraging turnaround (9.0x→~1.6x net leverage) that has tripled on AI-datacenter optionality — but the stock now prices that optionality at ~62x forward earnings while Credo owns ~88% of the very AEC market Semtech is fighting to enter; the moat is real in TVS/LoRa, not yet proven in datacenter interconnect. WATCHING, not chasing. | — | 8 |
| This is no longer a chip stock — it's a near-closed merger-arb. TI buys SLAB for $231 cash; HSR cleared and shareholders approved, only China SAMR left, ~6% gross spread to close in 1H2027. The trade is deal certainty, not IoT growth. | — | 1 |
| The MEMS-timing monopolist is being bid as if it has already won the AI clock — at ~35x sales and ~85x forward earnings, a flawless +88% quarter and the transformational Renesas deal are not just priced in, they are required. | — | 1 |
| SKYT is no longer a foundry — it is an IonQ deal-stub trading $38.40 vs a $35.00 closed-vote merger value, i.e. a +10% premium that is pure leveraged FTC-cleared bet on IonQ rallying past $60.13; the standalone foundry (43% Infineon, negative op cash flow, $22M cash) is the break-case floor, not the thesis. | — | 1 |
| Best-in-class EDA franchise temporarily wearing an Ansys-debt-and-amortization disguise — the GAAP "collapse" is accounting, not the business; the real risk is paying ~35x forward for a name whose Design-IP leg is structurally cracked and whose synergy math doesn't pay until FY2028. | — | 8 |
| The pure-play picks-and-shovels winner of AI-chip test, printing a vertical Q1'26 (+87%, $2.53 EPS) — but the stock fell ~14% on it because Q2 guidance steps DOWN sequentially and a ~54x P/E prices permanent acceleration; great business, demanding price, cyclical tape. NEUTRAL/WATCHING into the next print. | — | 8 |
| Best analog franchise on Earth, mid-cycle, fully priced — the FCF-inflection thesis is now consensus at ~40x forward and above Street targets; you're buying quality at a cyclical-optimism peak, with China share-loss the under-priced tail. WATCHING, not chasing. | — | 8 |
| A real moat in AEC reliability and an n-1 cost edge, riding a verticalizing AI-interconnect ramp — but ~84% of revenue sits in three hyperscalers and ~41x forward earnings already prices in the optical pivot working. Bullish business, expensive stock; conviction gated on customer diversification proving out. | — | 1 |
| The unglamorous AI-optics toll-collector — a 12%-gross-margin Thai contract manufacturer the market is now paying a 45× fabless multiple for; the business is genuinely inflecting (DCI +90%, 1.6T capacity doubling) but the price has front-run two years of execution AND ignores that co-packaged optics is a 2027+ structural axe over the whole pluggable-transceiver thesis. | — | 0 |
L Lightwave Logiccatalyst in 44d | A 35-year science project that just turned the corner from lab to foundry PDK — credible polymer-photonics platform now inside Tower & GlobalFoundries flows, but $237K of revenue against a $1.5B cap means you are buying a 2027-28 design-win option, financed by perpetual dilution, with a 17.7% short base betting it stays a promise. | — | 1 |
| The arms-dealer of the AI optics build-out — Lumentum owns ~50-60% of the 200G/lane EML laser chip that every 1.6T transceiver needs, NVIDIA just bought $2B of preferred to lock its capacity, and revenue is compounding ~90% YoY off a real telecom trough; but at ~52x forward earnings with two customers = ~40% of revenue and a $3.8B convertible stack now in-the-money, the price already discounts flawless execution. | — | 1 |
| A re-rated telecom-equipment turnaround wearing an AI-infrastructure mask — the optical/AI-RAN engine is real and accelerating, but the stock already prices the re-rating (P/E ~90, +109% in 12m) while ~92% of revenue is still slow-growth telecom/IP/patents. Right business, wrong entry. | — | 0 |
Q Quantum Computing Inccatalyst in 44d | A $2.5B market cap on $682K of FY25 revenue — QUBT is a $1.5B treasury wrapped in a photonics R&D lab, sold as a quantum-computing story; the balance sheet is real, the revenue is not, and a securities-fraud class action over the exact gap between the two is unresolved. | — | 1 |
| A well-run, deleveraging precision-motion roll-up whose ~0.8% organic growth has been lapped by a +99% / 12-month stock that now trades at ~67x P/E and ~24x EV/EBITDA — the SAME EBITDA multiple as Ametek at 1/20th the scale and quality, and ~20-45% above every published analyst target. Quality business, dislocated price. WATCHING / lean BEARISH on valuation, not on the company. |
| — |
| 8 |
| Not a robotics name — the purest large-cap pick-and-shovel on AI back-end networking (800G→1.6T switches + custom hyperscaler racks), compounding adjusted EPS ~45%/yr; but ~65% of revenue sits in three hyperscalers and the stock already prices ~37x forward, so the bet is "does hyperscaler capex and Celestica's share survive a single-customer wobble" rather than "is there demand." | — | 1 |
| A high-quality, asset-light machine-vision franchise mid-cyclical-recovery (Q1 '26 +21% cc, GM back to 71%, new CEO executing) — but the tape already prices a flawless multi-year re-acceleration at ~34x forward EPS, so the edge is in the cycle, not the multiple. WATCHING, not chasing. | — | 8 |
| A spine-implant roll-up wearing a robotics badge — the robot is <5% of revenue and a razor-and-blade pull-through, not the story; the real bet is whether mid-single-digit organic growth re-accelerates as NuVasive integration scars heal, at a justified ~16x value-medtech multiple. | — | 8 |
H Hesai Groupcatalyst in 44d | The clear global LiDAR volume leader, now GAAP-profitable and pivoting into physical-AI sensing — but the entire equity is hostage to a single binary it cannot control: the U.S. appeals-court ruling on its DoD "Chinese Military Company" designation, with a hard June 30 2026 contract-ban trigger. | — | 1 |
| A breakup that has already done its job on the multiple — automation re-rates fairly post-spin, aerospace (HONA) is the cleaner long, but at ~21x blended and with the catalyst (June 29) priced, the easy money is made; own HONA, hold/trim HON. | — | 8 |
I Innoviz Technologiescatalyst in 43d | A real Tier-1 LiDAR product with marquee OEM design wins, trading like an option that expires — the bet is whether VW/Mobileye SOP volume arrives before the Sept-2026 Nasdaq clock and the cash runway force a dilutive reverse split. | — | 1 |
| The best razor-and-blade in medtech, finally facing real razors — an 84%-recurring soft-tissue surgical monopoly compounding mid-teens, but priced at ~37x forward EPS just as Medtronic and J&J arrive and US procedure growth decelerates 19%→14-16%. Quality is not the question; the entry price is. | — | 0 |
| A newly-merged global #1 in food-processing automation, ~17% off its March high, mid-cycle on a real integration story — the bull case is synergy-and-deleveraging math the market half-believes; the bear case is two unremediated Marel control weaknesses and a $5.4B goodwill/intangible stack sitting on a still-cyclical protein-capex book. | — | 1 |
| A funded, certification-stage option on being the first FAA-certified eVTOL — real moat in vertical integration + a fortress balance sheet, but priced for flawless execution with zero core revenue and a binary 2026 catalyst. | — | 1 |
| A reserve-distorted GAAP optic hides a clean ~6-7% operational compounder that has visibly grown THROUGH the STELARA cliff; at ~20.6x forward adj EPS it is a quality-at-fair-price hold whose re-rate gate is talc tail-risk resolution and Orthopaedics/Ottava optionality, not the P&L. | — | 8 |
| A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof. | — | 1 |
| A real subsea-autonomy technology wrapped in a broken micro-cap balance sheet — going concern, a near-empty backlog, Q1-2026 revenue collapsed to $160k, and a board-authorized path to a cumulative 1-for-250 reverse split and 1.5B authorized shares. The tech may survive; today's common stock is a melting ice cube. | — | 1 |
| A real, well-run precision-photonics/motion compounder priced like a 38%-EPS-growth story while actually compounding GAAP earnings backwards (~2% over 5yr) — the whole thesis rests on restructuring + AI-datacenter mix converting ~3% organic growth into margin expansion; WATCH/NEUTRAL near $151, not a buy at ~40x forward / ~30x EV/EBITDA until margins inflect. | — | 8 |
| A real, accelerating Western digital-lidar franchise (+49% rev, 43% GM, 13 straight up quarters, June-30 NDAA China ban as a structural tailwind) priced like a winner-take-all at ~15x sales while it still burns cash and lives on serial dilution — own the operating turn, not this multiple. | — | 1 |
P Pony.aicatalyst in 44d | A genuine top-3 global robotaxi platform finally crossing city-level unit-economics breakeven — but priced for execution it has not yet earned, with a related-party-and-China-permit overhang that the −65% drawdown is screaming about; net-cash floor + founder 540-day lockup make it a WATCHING name to size on proof of fleet-scaling through the permit freeze, not a chase here. | — | 8 |
| A single-asset surgical-robotics razor-and-blade compounding ~30% real procedure growth, deliberately torching its own reported revenue to purge channel-stuffed handpieces and install pricing discipline — the half-off de-rate prices in a demand-saturation fear the procedure data does not yet confirm, and a TAVR-category-builder CEO is the call option the tape is ignoring. | — | 1 |
| A $5M-revenue, revenue-SHRINKING robot company trading at ~90x sales is really a $270M cash-box wrapped in a serial-dilution, AI-partnership-hype machine — now under a 10b-5 class action for a Microsoft "partnership" Microsoft denied; the only real value is the cash, and management is burning it while printing stock. | — | 0 |
| A 30-year never-profitable robotic-navigation company that finally owns its full stack (GenesisX robot + MAGiC catheter) and is one H2 manufacturing ramp away from the razor-and-blade flywheel turning — a binary execution call where the Street's $4+ targets price the ramp as a near-certainty the $6.3M Q1 print does not yet support. | — | 0 |
| A best-in-class MedTech compounder whose 8-9.5% organic engine is intact, but at ~20x forward EPS the stock already prices the cyber-attack recovery as a formality — the bet is that a $375M Q1 air-pocket is timing, not a dent in the franchise. | — | 8 |
| A serially-acquiring imaging-and-defense-electronics compounder dressed up under a "robotics" tag — high-quality, defense-levered, ~27x forward earnings with only mid-single-digit organic growth; quality is real, the margin of safety is not. NEUTRAL/WATCHING pending an organic-growth re-acceleration or a multiple reset. | — | 8 |
| A near-breakeven Chinese smart-EV OEM whose margin (GM 18.9% FY25, ~20% Q1'26) and a high-margin VW software-licensing annuity are real — but FY26 volume has rolled over (-22.6% YTD), and the IRON/eVTOL/robotaxi "embodied-AI" optionality the bulls pay for is unproven cash-burn; long the software+margin inflection at a 52-week-low multiple, but only if the GX/new-model cycle re-accelerates deliveries by 2H26. | — | 0 |
| A cheap, well-run AIDC compounder mis-tagged "robotics" — it just SOLD its robots; the real bet is whether ~4% organic hardware growth + buybacks + a tariff-refund kicker re-rates a 13x stub the Street already targets at $330. | — | 8 |
| The #1 knee/hip implant franchise priced for failure (~12x fwd EPS) — but it is the value trap until it proves organic growth can clear 3% without the Paragon/Monogram M&A crutch and stops losing the robotics war to Mako. Cheap is the thesis and the warning. | — | 8 |
A AST SpaceMobilecatalyst in 42d | A pre-revenue option on owning the only direct-to-unmodified-phone cellular layer in space — FCC-blessed and ~$4.5B-funded through ~90 satellites, but the entire bull case is a single binary that resolves in 2027: can it manufacture, launch, and switch on a 45–60 satellite constellation before Starlink's good-enough text/voice layer makes "broadband from space" a feature nobody pays a premium for. At ~$31B on $71M of 2025 revenue, the market is already paying for flawless execution it has not yet seen. | — | 0 |
| A debt-free, 59%-gross-margin device compounder mispriced as "space" — the real bet is whether the FY25–26 fitness-wearable share surge is a durable re-rating or a post-pandemic echo that decays back to mid-single-digit growth at a 24x multiple that already pays for the good case. | — | 8 |
| A balance-sheet roll-up of the fragmenting Western defense-satcoms supply chain (DataPath→Stellar Blu→Comtech) wrapped around an orbit-agnostic ground-terminal franchise that wins whether GEO or LEO wins — but the stock already prices the re-rating (~23x EV/EBITDA) while organic margins are still convalescing and two customers are 44% of revenue. | — | 1 |
| GSAT is no longer a fundamental story — it is an Amazon merger-arb at $90/sh (≈10.8% gross spread, 2027 close); buy the deal-break protection (Apple re-signed, $592M reverse break fee, FCC defends the spectrum, vote already done), not the satellites. The only real risk is regulatory drag, not deal failure. | — | 0 |
| Best-in-class aerospace-aftermarket compounder firing on all engines (18% organic, record margins) — but the moat is in the price; at ~60x forward earnings the stock is a great company priced as a bond you can never lose on, and any organic deceleration re-rates it hard. | — | 0 |
| A debt-levered, cash-machine LEO monopoly being re-rated on spectrum scarcity — own the durable EMSS/IoT/Aireon annuity, but the spectrum-takeout dream is now mostly in the price. | — | 1 |
| A spec-locked, sole-source space-and-defense subsystem roll-up riding Golden Dome and OBBBA tailwinds at ~50% growth — but it is a leveraged (2.1x D/E) PE-sponsor exit story with a live material weakness, ~$680M of floating-rate debt, and a still-rich ~34x forward EV/Adj-EBITDA; the 58% drawdown is a Trive-Capital supply unwind, not a thesis break. WATCHING (coverage note: this is fundamentally a defense prime-supplier — see exclusion flag). | — | 1 |
| A commercial-imagery company that quietly became a sovereign-defense satellite-services contractor — the backlog (+72%) and the Rule-of-40 inflection are real, but a $1.5B ATM on top of ~30x sales means the bet is now whether durable government demand outruns relentless dilution. | — | 1 |
| A real, accelerating dual-use (space + combat-proven drones) franchise welded onto a still-loss-making, AEI-controlled, serial-dilution SPAC — the business is finally interesting but the cap table and cash burn are doing the pricing; WATCHING, not yet ownable, until the ATM overhang clears and adjusted EBITDA turns. | — | 8 |
| A $20M-revenue EO manufacturer trading like a $1B growth story on a 200% YTD re-rate — the cost-per-satellite edge and Tether-backed balance sheet are real, but the price already discounts a Merlin success that hasn't launched, and three customers are half the revenue. | — | 1 |